Inventiva S.A. (IVA) Stock
IVA has an Alpha Score of 29 out of 100 (poor), computed on Aug 23, 2026 from 3 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported IVA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $13.28M.
What is IVA's Alpha Score?
How it works →Alpha Score of 29 reflects poor overall profile with weak momentum, poor value, poor quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 23, 2026 · 60 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own IVA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 3.51M | $13.28M | +18% |
| Citadel Ken Griffin | 1.78M | $6.75M | +2648% |
| Point72 Steve Cohen | 1.68M | $6.36M | +76% |
| Marshall Wace | 966K | $3.65M | +48% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are IVA's key statistics?
Key statistics as of Oct 22, 2026
IVA price chart
Powered by TradingViewWhat does Inventiva S.A. do?
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. With its research and development headquarters situated in France, the company dedicates its efforts to designing treatments for diseases with significant unmet medical needs, particularly in the fields of oncology, fibrosis, and genetic diseases. A key aspect of Inventiva's strategy involves utilizing its deep expertise in the field of nuclear receptor biology and transcription factors to develop innovative medicines. Inventiva also applies its proprietary technologies to facilitate the discovery of novel candidates through sophisticated screening techniques and biological assays. The company plays a notable role in the pharmaceutical sector, engaging in collaborations with leading global healthcare entities to expedite drug development processes. By advancing promising drug candidates through clinical trials, Inventiva aims to bring transformative therapies to the market, ultimately enhancing patient care and addressing critical health challenges globally. The significance of their work is underscored by the potential impact on treatment paradigms for diseases currently lacking effective therapeutic options.